NeuroNOS Acquires XTL Biopharmaceuticals Ltd. to

NeuroNOS has acquired XTL Biopharmaceuticals Ltd. for $1.0 million.

XTL Biopharmaceuticals, a clinical-stage biotech company, specializes in the development of pharmaceutical products for autoimmune diseases, with a primary focus on systemic lupus erythematosus (SLE).

This transaction marks a strategic expansion for NeuroNOS into the autoimmune therapeutic area.

XTL Biopharmaceuticals' lead drug candidate, hCDR1, is a world-class clinical asset specifically designed for the treatment of systemic lupus erythematosus (SLE).

The company has generated robust clinical data for hCDR1 across three clinical trials involving 400 patients, alongside over 200 preclinical studies, with findings published in more than 40 peer-reviewed scientific journals.

Current treatments for SLE often lack sufficient efficacy for many patients and can present significant side effects, underscoring the substantial unmet medical need that hCDR1 aims to address within the patient community.

The acquisition of XTL Biopharmaceuticals by NeuroNOS is strategically driven by the opportunity to integrate a promising late-stage clinical asset into NeuroNOS's existing portfolio.

This move allows NeuroNOS to immediately gain a significant foothold in the autoimmune disease market and leverage XTL's specialized expertise and extensive research in lupus.

The synergy is expected to accelerate the development pathway for hCDR1, combining XTL's established scientific foundation with NeuroNOS's operational capabilities and broader market reach.

Looking ahead, the combined entity is positioned to advance the hCDR1 program with renewed focus and enhanced resources.

This acquisition is anticipated to significantly strengthen NeuroNOS's overall therapeutic pipeline and enhance its presence within the competitive biopharmaceutical sector, particularly in addressing complex and underserved autoimmune conditions like SLE.